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1

This study aimed to evaluate well-documented diagnostic antigens, named B13, 1F8 and JL7 recombinant proteins,
as potential markers of seroconversion in treated chagasic patients. Prospective study, involving 203 patients treated
with benznidazole, was conducted from endemic areas of northern Argentina. Follow-up was possible in 107 out of
them and blood samples were taken for serology and PCR assays before and 2, 3, 6, 12, 24 and 36 months after treatment initiation. Reactivity against Trypanosoma cruzi lysate and recombinant antigens was measured by ELISA. The
rate of decrease of antibody titers showed nonlinear kinetics with an abrupt drop within the first three months after
initiation of treatment for all studied antigens, followed by a plateau displaying a low decay until the end of follow-up.
At this point, anti-B13, anti-1F8 and anti-JL7 titers were relatively close to the cut-off line, while anti-T. cruzi antibodies
still remained positive. At baseline, 60.8% (45/74) of analysed patients tested positive for parasite DNA by PCR and during the follow-up period in 34 out of 45 positive samples (75.5%) could not be detected T. cruzi DNA. Our results suggest
that these antigens might be useful as early markers for monitoring antiparasitic treatment in chronic Chagas disease.
Key words: Trypanosoma cruzi - chronic Chagas disease - benznidazole treatment - serological follow-up - adverse effects

Chagas disease or American trypanosomiasis,
caused by the parasite Trypanosoma cruzi, is endemic in
much of the Americas, from the southern United States
to Argentina and Chile. It is the fourth most common
tropical disease, after malaria, tuberculosis and schistosomiasis, currently affecting 7-6 million people (WHO
2015). The risk of infection with T. cruzi is directly related to poverty, but due to migrations, several cases have
been reported throughout the world (Lescure et al. 2008,
Muñoz et al. 2009, Jackson et al. 2010).
In Argentina, it is estimated as many as 1.5 million
patients have Chagas disease and 2.2 million people in
risk of T. cruzi infection (WHO 2015). The endemic area
covers the north of the country where the conditions,
such as high levels of poverty and social exclusion, low
population density, mostly rural, subsistence economy,
and a weak health system, favor not only T. cruzi infection but also for the development of this disease.
Once the individual acquires the parasite, the infection starts with an acute phase, followed by a chronic stage

doi: 10.1590/0074-02760160006
Financial support: Fundación Bunge and Born, CONICET.
† In memoriam
+ Corresponding author: longhi@dna.uba.ar
Received 11 January 2016
Accepted 15 April 2016

which includes asymptomatic and symptomatic cases,
with cardiac, digestive manifestations or mixed patterns
(WHO 2015). Up to now, the available treatment is based
on two drugs: nifurtimox and benznidazole (BNZ). Chemotherapy against T. cruzi infection is strongly recommended for all cases during the acute stage, in children
under 15 years old and reactivated infections in immunocompromised patients (Bianchi et al. 2015), but its effectiveness during the chronic stages is still under revision
(Cançado 2002, Viotti et al. 2006, 2014). Some studies
suggest that BNZ for asymptomatic or early symptomatic
cases may improve parasite clearance rates (de Andrade
et al. 1996, Sosa-Estani et al. 1998). In 1999, a panel of
experts reached the consensus that patients with chronic
Chagas disease should be treated with an anti-T. cruzi
medication (PAHO 1999). From this recommendation,
many studies are being conducted. Thus, results from a
multicenter, placebo-controlled trial involving BNZ for
the treatment of Chagas cardiomyopathy showed that
the drug significantly diminished serum parasite detection, but did not improve cardiac clinical manifestation
(Morillo et al. 2015). In parallel, another trial with longterm follow-up in adult patients, is being conducted in
Argentina to evaluate whether BNZ treatment change the
evolution of chronic Chagas disease (Riarte 2013). Other
randomised clinical studies, with shorter follow-up periods, based on the safety and efficacy of new drugs such
as posaconazole, studied this drug alone or in combination with BNZ (Molina et al. 2014, and STOP CHAGAS
clinical trial, Identifier: NCT01377480).
online | memorias.ioc.fiocruz.br
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After treatment, the criterion of cure in chronic Chagas disease is the persistence of negative parasitological
and serological results (Porrás et al. 2015). Unfortunately, T. cruzi lysate antibody seroconversion occurs several years after antiparasitic therapy in most individuals,
while parasitological methods are consistently negative (Guedes et al. 2011, Machado-de-Assis et al. 2012).
Thus, the identification of early markers of seronegative
conversion is an important and imperative step to evaluate Chagas disease treatment.
The aim of this study was to evaluate if well-known serological markers could have an early predictive value and
be useful to monitor drug therapy response, by measuring
antibody (Ab) levels over time in a cohort of patients with
chronic Chagas disease treated with BNZ. For this purpose,
we selected the recombinant proteins named B13, 1F8 and
JL7, because they are recognised by most chronic chagasic
patients and are currently used in commercial kits for diagnosis (Umezawa et al. 1999, 2003, Ponce et al. 2005).

HCl/0.2 M EDTA buffer pH: 8.0. Guanidine-EDTA blood
(GEB) was heated for 15 min in boiling water and total
DNA was purified from 500 µL GEB with phenol-chloroform-isoamyl alcohol (25:24:1, V/V) as previously reported (Schijman et al. 2003). The 330-bp variable regions
of the T. cruzi kinetoplastid minicircle genome was amplified with 121 [5′-AAATAATGTACGG G(T/G)GAGATGCATGA-3′] and 122 (5′-GGTTCGATTGGGGTTGGTGTAATATA-3′) primers by conventional PCR as
previously described (Schijman et al. 2003).

SUBJECTS, MATERIALS AND METHODS

Enzyme-linked immunosorbent assay (ELISA) - Inhouse ELISAs were carried out as described previously
(Longhi et al. 2012). Briefly, microwells (Costar Inc.,
Corning, NY) were coated overnight at 4ºC with T. cruzi
lysate (20 μg/mL) or B13, 1F8 and JL7 recombinant proteins (5 μg/mL) in 50 μL of 0.05 M carbonate-bicarbonate buffer (pH 9.6). The plates were washed thrice with
washing buffer (PBS containing 0.1% Tween-20; PBS-T)
and then blocked with PBS-T plus 5% non-fat dry milk
for 1 h at 37ºC. Sera diluted 1:200 in PBS-T with 1%
non-fat dry milk were incubated in duplicate for 2 h at
37ºC. To avoid test variability, serum samples (from T0T6) from a given patient were assayed on the same plate
and sera from eight healthy individuals were also loaded
on each plate to determine cut-off value.
After the plates were washed three times, 50 μL of alkaline phosphatase (for T. cruzi lysate) or peroxidase (for
recombinant proteins) conjugated anti-human polyvalent
immunoglobulins diluted 1:3000 in PBS-T containing
1% non-fat dry milk, was dispensed into each well and
incubated 1 h at 37ºC. The reaction was developed with
p-nitrophenyl phosphate (for alkaline phosphatase) or 3,
3’, 5, 5’ - tetramethylbenzidine substrate (for peroxidase)
and read at 415 nm or 450 nm, respectively.
In parallel, some serum samples were also analysed
by commercial Chagatest ELISA recombinant v4.0
(Wiener Laboratory, Rosario, Argentina) according to
manufacturer’s instruction.

Patients and study design - Prospective study was carried out from years 2000-2004 in Añatuya, a city located
in a highly Chagas disease-endemic area in the Province of Santiago del Estero - Argentina. Three hundred
and twelve T. cruzi-infected adults volunteers aged 15-55
years were recruited and 270 patients in the asymptomatic
or cardiac chronic phase of Chagas disease were eligible.
Inclusion criteria were positive diagnostic for Chagas
disease by commercial ELISA and indirect hemagglutination assays, according to Argentina’s National Guidelines
and the World Health Organization (WHO) recommendations. Exclusion criteria included the visceral damage,
presence of systemic arterial hypertension, liver or kidney failure, severe cardiac lesions associated with other
cardiac diseases, pregnancy, lactation, alcoholism and
hypersensitivity to the drug. BNZ was given three times
daily over 60 days at a total dose 5 mg/kg/day (100 mg/
tablet: Radanil, Roche). During treatment, patients were
subjected to clinical examination to evaluate side effects.
Blood samples were collected at the following instances: T0, before treatment; T1, two months; T2, three
months; T3, six months; T4, one year; T5, two years and
T6, three years after treatment onset, respectively.
The research protocol followed the tenets of the
Declaration of Helsinki and was approved by the Local
Medical Ethics Committees named Comité Institucional
de Ética de Investigación en Salud - Ministerio de Salud
y Desarrollo Social de Santiago del Estero and Comité
de Ética del Hospital Zonal de Añatuya Monseñor Gottau. Before and during the beginning of this study, the
area was under triatominae vector surveillance by official government sanitary agents and Mundo Sano Private Foundation (i.e., they undertook regular insecticidal
actions against infestations). All enrolled adult patients
gave written informed consent and the parent or guardian
of the child participants provided informed consent on
their behalf after the nature of the study was explained.
DNA extraction and amplification - Blood samples
were mixed with an equal volume of 6 M guanidine

Parasite lysate and recombinant proteins - Parasite
extracts were obtained from T. cruzi epimastigotes CLBrener strain DTU Tc VI (Zingales et al. 2009), as previously described (Gómez et al. 2001).
B13, 1F8 and JL7 were expressed as GST fusion proteins and purified by affinity chromatography on glutathione-agarose beads as previously described (Umezawa et
al. 1999). Protein contents were quantified by Bradford reagent, and all antigens were maintained at -80ºC until used.

Statistical analysis - Chi-square test for the analysis
of drug side-effects were performed. Longitudinal panel
data analysis was used to assess the change in Ab levels
over time. Longitudinal data was analysed using generalised linear mixed effects modelling, as implemented
in R software 2.10.0 version (R Core Team 2013), with
random effects specified at the level of the individual.
Normal distribution of dependent variables was evaluated
with Shapiro-Wilks test. Variables not normally distributed were log-transformed before analysis and log-normality confirmed with Shapiro-Wilks test for the transformed
variables. Estimation of 95% confidence intervals (95%
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Fig. 1: flow diagram of patient enrollment, treatment and follow-up.

CI) for generalised linear mixed effects regressions was
done by Markov Chain Monte Carlo, as implemented in
WinBUGS and R (R Core Team 2013). Statistical significance was assumed at p < 0.05 or 95% CI.
RESULTS AND DISCUSSION

Several recombinant antigens are used for diagnosis
of Chagas disease (Afranchino et al. 1989, dos Santos et
al. 1992, Krieger et al. 1992, Umezawa et al. 1999, 2003,
Di Noia et al. 2002, Camussone et al. 2009, De Marchi
et al. 2011), but none of them has been tested as early
markers of cure after anti-parasitic treatment. With this
idea in mind, we decided to determine the level of antibodies against three antigens, namely B13, 1F8 and JL7,
in a cohort of patients treated with BNZ by an in-house
ELISA method. These antigens correspond to repeat
tandem proteins of T. cruzi and have been well described
in other works as immunodominant antigen in Chagas
disease (Umezawa et al. 1999, 2003, Longhi et al. 2012).
Flowchart of enrollment, treatment and follow-up is
schematised in Fig. 1. Sixty seven out of 270 enrolled
patients (24.8%) interrupted treatment, because of death
(2/67, 2.9%), pregnancy (4/67, 5.9%), fail to correctly follow medical prescription or adverse effects (24/67, 35.8%)
and voluntary abandonment (37/67, 55.2%). Although 203
completed drug therapy, only three or more follow-up
samples could be obtained in 107 treated patients, especially due to difficulties of patients to attend to hospital
during three years of drug monitoring. The number of
samples analysed from T0-T6 is shown in Table. It is important to mention that the group of patients analysed was
representative of the total cohort that completed treatment
with similar rates of females/males and rural/urban residents (Fig. 1). Moreover, mean age of patients who completed treatment (34.5 years, N = 203) or follow-up (35.7
years, N = 107) was also comparable, with a higher proportion of patients ranged in age from 25-44 years (65%;
132/203 and 68%; 73/107, respectively).

TABLE
Number of samples analysed during the benznidazole follow-up

T0
T1
T2
T3
T4
T5
T6

Timea

Nb

0
2
3
6
12
24
36

107
104
106
104
73
65
60

Time in months from treatment onset; bNumber of serum samples.

a

As it has been previously reported (Viotti et al. 2009,
Pinazo et al. 2010) typical side effects, generally mild
and transient, were observed in 67 out of 203 patients
who complete treatment. The most common side effect
proved cutaneous hypersensitivity (29/203, 14.3%) such
as pruritus, allergy and exanthema, followed by digestive disorders (18/203, 8.8%) as epigastric pain, dyspepsia and heartburn. In addition, 11 out of 203 patients
(5.4%) presented headache, nauseas or vomiting, while
nine patients suffered arthralgia and myalgia (4.4%).
The appearance of more than one side effect was only
observed in 12 out of 203 patients (5.9%). The incidence
of adverse reactions was not statistically associated to
age, sex, or place of residence -urban or rural areas(Chi-square test, p = 0.43, p = 0.26, p = 0.96, respectively). It is important to highlight that a high number
of patients, who developed cutaneous hypersensitivity,
worked in brick factories exposed to heat and sunlight.
Parasitological experiments were performed in 74
out of 107 patients. At baseline, 60.8% (45/74) had posi-
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Fig. 2: antibody levels. ELISA plates were coated with Trypanosoma cruzi lysate, or B13, 1F8 and JL7 recombinant proteins in buffer carbonate.
Serum samples were diluted 1/200 and tested in duplicate. Results are
expressed as optical density (OD) means for each antigen ± standard error
of the means (SEM). Cut-off values for T. cruzi, B13, 1F8 and JL7 recombinant proteins, were 0.276, 0.110, 0.367 and 0.150, respectively.

tive results for T. cruzi PCR, whereas during monitoring
period, consistently negative PCR results were documented in 34/45 (75.5%). Similar data have been reported by Morillo et al. (2015) in BENEFIT trial, showing
that T. cruzi DNA was not detected in 73% of Argentinian and Bolivian patients at the end of follow-up. However, CHAGASAZOL trial reported that 94% of patients
treated with BNZ tested negative by PCR (Molina et al.
2014). These differences could be related to the risk of
exposure to the parasite, because patients included in
CHAGASAZOL trial have been living in Barcelona,
Spain - a non-endemic area - during the whole study.
On the contrary, although the area was under triatominae vector surveillance, the study population in BENEFIT trial and in our work belonged to endemic regions,
where there is a real risk of exposure to reinfections, due
to population movement to areas without vector control.
After analysing serologic response against T. cruzi
lysate or recombinant proteins by linear mixed effects
modelling, we observed an apparent biphasic curve for all
antigens, with an initial rapid decline within the first three
months followed by a plateau with a slight decay for the
remaining 36 months of follow-up (Fig. 2). The decrease
in Ab titers against T. cruzi lysate over time was -0.0075
optical density (OD)/month (95% CI -0.0060 to -0.0090]),
with a significant effect of time for each patient (Supplementary figure). Similar results were obtained for Ab anti-B13, anti-1F8 and anti-JL7 levels with a slope of -0.0032
OD/month for B13 (95% CI [-0.0010 to-0.0074], -0.0041
OD/month for 1F8 (95% CI [-0.0001 to -0.0083]) and
-0.0032 OD/month for JL7 (95% CI [-0.0009 to -0.0075]),
with significant effect for each patient as a function of
time (Supplementary figure). A statistically significant

faster rate of decline was observed for Ab titers against
T. cruzi lysate in comparison to anti-B13, anti-1F8 and
anti-JL7 (p < 0.01 for all comparisons, linear mixed effects model analysis). Indeed, results showed that the OD
mean values for recombinant proteins declined progressively close to the cut-off values at the end of the followup, while those for T. cruzi lysate remained positive (Fig.
2). This observation could be explained by the fact that
sera reactivity at T0 is higher to T. cruzi lysate than with
recombinant proteins. This data is in accordance with
results presented by others, who observed a low rate of
seronegative conversion of anti-T. cruzi response detected
by conventional serological test (Sosa-Estani et al. 1998,
2009, Viotti et al. 2011, Machado-de-Assis et al. 2013).
It is important to highlight that most sera presented
reactivity against T. cruzi lysate and the recombinant
proteins, as for example the Patient #115 (Fig. 3), but
some patients did not developed detectable Ab against
all the recombinant antigens. As shown in Fig. 3, serum
from Patient #207 did not react with the three studied
recombinant antigens and along with serum from Patient
#7 were the only two samples that showed low reactivity
against B13. Likewise five patients had a similar pattern
response as Patient #131, seven patients as Patient #85
and 12 patients as Patient #27 without reactivity to 1F8
and/or JL7 (Fig. 3). In this cohort of patients, the percentage of reactivity against B13, 1F8 and JL7 was 98, 89 and
82, respectively. Based on these finding, we suggest that
no single recombinant protein would be useful for the
assessment of therapeutic response in all patients, and
reactivity against the three antigens should be tested individually for future treatment evaluation.
In parallel for comparison purpose, sera reactivity was
determined by a commercial Chagatest ELISA recombinant. As shown in Fig. 3, a similar pattern response to T.
cruzi lysate was obtained, with a slight decrease in Ab
levels, but without showing a seroconversion at end of
follow-up, while as mentioned above, anti-B13, anti-1F8
and anti-JL7 Ab declined progressively close to the cutoff values at the end of follow-up. Finally, we observed
along to monitoring that Patients #115, #131, #7, #85 and
#27 showed decay in Ab response, especially against to
recombinant antigens (Fig. 3) and also tested negative for
T. cruzi DNA by PCR. On the contrary, Patient #207, who
had no changes in reactivity against T. cruzi lysate (Fig.
3), PCR assays remained positive during the follow-up.
Throughout the years, there have been major advances in the control of T. cruzi transmission due to vector control by insecticide spraying, but little has been
achieved in terms of treatment of infected people. The
fact that most of those infected individuals are from the
poorer strata of society diminishes the interest in the development of new drugs by the pharmaceutical companies, but it is one of the priorities for WHO in the control
of Chagas disease. Therefore, therapy efficacy or drug
success necessarily requires validate an accurate method
to evaluate the course of the disease (Pinazo et al. 2014).
As mentioned above, positive prognosis after antiparasite treatment often is made by serological and/or
parasitological subsequent examinations with consistently negative results in time (Porrás et al. 2015). Non-
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Fig. 3: variation in optical density (OD) by the ELISA as a function of time. Results from six patients, representing typical pattern response against Trypanosoma cruzi lysate, B13, 1F8 and JL7 recombinant proteins, are schematised. Chagatest ELISA recombinant v4.0 results were included in comparison
of in-house ELISAs. Cut-off values for T. cruzi, Chagatest, B13, 1F8 and JL7 recombinant proteins, were 0.276, 0.126, 0.110, 0.367 and 0.150, respectively.

conventional serological methods, including a multiplex
format or ELISA with recombinant proteins, have been
developed to provide fast, easy to measure, responses to
etiological treatments (Cooley et al. 2008, FernándezVillegas et al. 2011, Fabbro et al. 2013). However, there
are no consensuses about which is the gold standard of

post-treatment evaluation protocols to establish cure in a
reasonably short time (Urbina 2015).
Overall, our results showed that none of the patients
showed a seronegative conversion for anti-T. cruzi response during the follow-up, but a significant decay in
the Ab titer against recombinant antigens was observed
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in the majority of the patients with chronic Chagas disease three years after the end of specific drug treatment.
Since, the level of Ab against recombinant proteins
B13, 1F8 and JL7 decreased to cut-off line earlier than
Ab against T. cruzi lysate and these reduction were not
statistically associated to age, sex, or place of residence,
results suggest that these antigens would be good candidates as early markers of serological response to evaluate
drug success. Although the main limitations of our study
were the non-randomised design, and absence of a placebo control group due to bioethics considerations of the
Local Medical Ethics Committee, our findings encourage
further evaluation of these recombinant antigens in randomised and controlled trial with trypanocidal drugs.
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1

Linear mixed effects modelling. ELISA plates were coated with Trypanosoma cruzi lysate, or B13, 1F8 and JL7 recombinant proteins in buffer
carbonate. Serum samples were diluted 1/200 and tested in duplicate. Each point corresponds to optical density (OD) mean value for each patient
as function of time. Bold lines represent linear mixed effects regression, and grey zone 95% confidence intervals. Cut-off values for T. cruzi,
B13, 1F8 and JL7 recombinant proteins, were 0.276, 0.110, 0.367 and 0.150, respectively.
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